The Relative Strength (RS) Rating for Roivant Sciences entered a higher percentile Thursday, as it got a lift from 67 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an 80 or better RS Rating in the early stages of their moves. See if Roivant Sciences can continue to show renewed price strength and clear that threshold.
Roivant Sciences is building a consolidation with a 13.05 entry. See if the stock can break out in heavy trade.
The company posted 0% earnings growth last quarter. Revenue rose -73%.
The company holds the No. 277 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
